Advanced Optima eXPert software provides unprecedented centrifugation capabilities. It assists in developing the most efficient centrifugation methods, selecting the rotor and labware for a given application, then simulating the results before performing separations of proteins and sub-cellular particles. The innovative rotors built for the Optima L-XP are designed, manufactured and tested as a system from the inside out to get the highest quality of separation in the shortest possible time-safely and reliably. The increased efficiency of SW 32 Ti series rotors can reduce run times. The patented NVT rotors deliver the highest purity in the shortest possible time. Optima L-XP utilizes the most advanced materials and technology to achieve the high performance needed for extending the boundaries of research. And the imbalance-tolerant Optima L-XP drive safely accommodates tubes that are under- or over-filled by as much as 10%. The design of one-touch OptiSeal tubes delivers fast, reliable sealing--just insert the plug and press into place, and the centrifugation process itself provides guaranteed protection for samples.

Description

Optima L-XP ultracentrifuge is designed to play a key role in the discovery process if research involves proteomics, cytomics or genomics. It has a sophisticated on-board computer, enhanced firmware, powerful Optima eXPert software and an easy-to-use touch screen, Optima L-XP delivers superior functionality, optimized user efficiencies, far greater capabilities and faster turnarounds than any other ultracentrifuge.

(Date:12/8/2016)... ... December 08, 2016 , ... The West Virginia ... 1, 2017. The name change aligns the entire company with its existing ... care quality. , “We are very proud of the achievements associated with the ...

(Date:12/8/2016)... -- KEY FINDINGS North America ... in 2016 and is expected to continue in the ... large number of surgical procedures that are taking place ... the patient temperature management market.) Patient warming and cooling ... blood during surgeries, lowering the risks of neurological disorders ...

(Date:12/8/2016)... Dec. 8, 2016 Eli Lilly and Company (NYSE: ... its phase 3 EXPEDITION3 trial at the 9 th ... previously disclosed, solanezumab did not meet the primary endpoint ... initiated in people with mild dementia due to Alzheimer,s ... for solanezumab for the treatment of mild dementia due ...